nodes	percent_of_prediction	percent_of_DWPC	metapath
Sirolimus—ABCB1—peripheral nervous system neoplasm	0.268	1	CbGaD
Sirolimus—CYP3A7-CYP3A51P—Tretinoin—peripheral nervous system neoplasm	0.0523	0.134	CbGbCtD
Sirolimus—CYP3A7—Tretinoin—peripheral nervous system neoplasm	0.0523	0.134	CbGbCtD
Sirolimus—CYP3A5—Tretinoin—peripheral nervous system neoplasm	0.0392	0.1	CbGbCtD
Sirolimus—ABCB1—Topotecan—peripheral nervous system neoplasm	0.0275	0.0703	CbGbCtD
Sirolimus—ABCB1—Alitretinoin—peripheral nervous system neoplasm	0.0275	0.0703	CbGbCtD
Sirolimus—CYP3A7—Vincristine—peripheral nervous system neoplasm	0.024	0.0615	CbGbCtD
Sirolimus—CYP3A7-CYP3A51P—Vincristine—peripheral nervous system neoplasm	0.024	0.0615	CbGbCtD
Sirolimus—ABCB1—Dactinomycin—peripheral nervous system neoplasm	0.019	0.0487	CbGbCtD
Sirolimus—CYP3A5—Vincristine—peripheral nervous system neoplasm	0.018	0.0461	CbGbCtD
Sirolimus—CYP3A5—Etoposide—peripheral nervous system neoplasm	0.0165	0.0423	CbGbCtD
Sirolimus—CYP3A4—Topotecan—peripheral nervous system neoplasm	0.0164	0.0421	CbGbCtD
Sirolimus—CYP3A4—Tretinoin—peripheral nervous system neoplasm	0.0153	0.0392	CbGbCtD
Sirolimus—ABCB1—Vincristine—peripheral nervous system neoplasm	0.0117	0.03	CbGbCtD
Sirolimus—ABCB1—Cisplatin—peripheral nervous system neoplasm	0.0109	0.028	CbGbCtD
Sirolimus—ABCB1—Etoposide—peripheral nervous system neoplasm	0.0107	0.0275	CbGbCtD
Sirolimus—ABCB1—Doxorubicin—peripheral nervous system neoplasm	0.00732	0.0188	CbGbCtD
Sirolimus—CYP3A4—Vincristine—peripheral nervous system neoplasm	0.00702	0.018	CbGbCtD
Sirolimus—CYP3A4—Etoposide—peripheral nervous system neoplasm	0.00643	0.0165	CbGbCtD
Sirolimus—CYP3A4—Doxorubicin—peripheral nervous system neoplasm	0.00439	0.0112	CbGbCtD
Sirolimus—Temsirolimus—ABCB1—peripheral nervous system neoplasm	0.000669	0.532	CrCbGaD
Sirolimus—Tacrolimus—ABCB1—peripheral nervous system neoplasm	0.000589	0.468	CrCbGaD
Sirolimus—Gastrointestinal disorder—Cisplatin—peripheral nervous system neoplasm	6.65e-05	0.00027	CcSEcCtD
Sirolimus—Pancytopenia—Epirubicin—peripheral nervous system neoplasm	6.6e-05	0.000268	CcSEcCtD
Sirolimus—Hypotension—Etoposide—peripheral nervous system neoplasm	6.59e-05	0.000268	CcSEcCtD
Sirolimus—Gastritis—Doxorubicin—peripheral nervous system neoplasm	6.59e-05	0.000268	CcSEcCtD
Sirolimus—Pain—Cisplatin—peripheral nervous system neoplasm	6.59e-05	0.000268	CcSEcCtD
Sirolimus—Alanine aminotransferase increased—Doxorubicin—peripheral nervous system neoplasm	6.57e-05	0.000267	CcSEcCtD
Sirolimus—Dysuria—Epirubicin—peripheral nervous system neoplasm	6.5e-05	0.000264	CcSEcCtD
Sirolimus—Neutropenia—Epirubicin—peripheral nervous system neoplasm	6.5e-05	0.000264	CcSEcCtD
Sirolimus—Asthenia—Alitretinoin—peripheral nervous system neoplasm	6.48e-05	0.000264	CcSEcCtD
Sirolimus—Abdominal distension—Doxorubicin—peripheral nervous system neoplasm	6.48e-05	0.000263	CcSEcCtD
Sirolimus—Upper respiratory tract infection—Epirubicin—peripheral nervous system neoplasm	6.46e-05	0.000263	CcSEcCtD
Sirolimus—Influenza—Doxorubicin—peripheral nervous system neoplasm	6.43e-05	0.000262	CcSEcCtD
Sirolimus—Dysphagia—Doxorubicin—peripheral nervous system neoplasm	6.43e-05	0.000262	CcSEcCtD
Sirolimus—Asthma—Doxorubicin—peripheral nervous system neoplasm	6.43e-05	0.000262	CcSEcCtD
Sirolimus—Pollakiuria—Epirubicin—peripheral nervous system neoplasm	6.42e-05	0.000261	CcSEcCtD
Sirolimus—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	6.42e-05	0.000261	CcSEcCtD
Sirolimus—Pruritus—Alitretinoin—peripheral nervous system neoplasm	6.39e-05	0.00026	CcSEcCtD
Sirolimus—Feeling abnormal—Cisplatin—peripheral nervous system neoplasm	6.35e-05	0.000258	CcSEcCtD
Sirolimus—Paraesthesia—Etoposide—peripheral nervous system neoplasm	6.34e-05	0.000258	CcSEcCtD
Sirolimus—Weight increased—Epirubicin—peripheral nervous system neoplasm	6.33e-05	0.000257	CcSEcCtD
Sirolimus—Pancreatitis—Doxorubicin—peripheral nervous system neoplasm	6.31e-05	0.000256	CcSEcCtD
Sirolimus—Weight decreased—Epirubicin—peripheral nervous system neoplasm	6.29e-05	0.000256	CcSEcCtD
Sirolimus—Dyspnoea—Etoposide—peripheral nervous system neoplasm	6.29e-05	0.000256	CcSEcCtD
Sirolimus—Hyperglycaemia—Epirubicin—peripheral nervous system neoplasm	6.27e-05	0.000255	CcSEcCtD
Sirolimus—Somnolence—Etoposide—peripheral nervous system neoplasm	6.27e-05	0.000255	CcSEcCtD
Sirolimus—Asthenia—Vincristine—peripheral nervous system neoplasm	6.25e-05	0.000254	CcSEcCtD
Sirolimus—Pneumonia—Epirubicin—peripheral nervous system neoplasm	6.24e-05	0.000254	CcSEcCtD
Sirolimus—Infestation NOS—Epirubicin—peripheral nervous system neoplasm	6.2e-05	0.000252	CcSEcCtD
Sirolimus—Infestation—Epirubicin—peripheral nervous system neoplasm	6.2e-05	0.000252	CcSEcCtD
Sirolimus—Vomiting—Dactinomycin—peripheral nervous system neoplasm	6.2e-05	0.000252	CcSEcCtD
Sirolimus—Bronchitis—Doxorubicin—peripheral nervous system neoplasm	6.19e-05	0.000252	CcSEcCtD
Sirolimus—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	6.18e-05	0.000251	CcSEcCtD
Sirolimus—Rash—Dactinomycin—peripheral nervous system neoplasm	6.15e-05	0.00025	CcSEcCtD
Sirolimus—Decreased appetite—Etoposide—peripheral nervous system neoplasm	6.13e-05	0.000249	CcSEcCtD
Sirolimus—Pancytopenia—Doxorubicin—peripheral nervous system neoplasm	6.11e-05	0.000248	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	6.09e-05	0.000248	CcSEcCtD
Sirolimus—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	6.09e-05	0.000247	CcSEcCtD
Sirolimus—Neuropathy peripheral—Epirubicin—peripheral nervous system neoplasm	6.08e-05	0.000247	CcSEcCtD
Sirolimus—Stomatitis—Epirubicin—peripheral nervous system neoplasm	6.04e-05	0.000246	CcSEcCtD
Sirolimus—Pain—Etoposide—peripheral nervous system neoplasm	6.03e-05	0.000245	CcSEcCtD
Sirolimus—Constipation—Etoposide—peripheral nervous system neoplasm	6.03e-05	0.000245	CcSEcCtD
Sirolimus—Conjunctivitis—Epirubicin—peripheral nervous system neoplasm	6.03e-05	0.000245	CcSEcCtD
Sirolimus—Urinary tract infection—Epirubicin—peripheral nervous system neoplasm	6.03e-05	0.000245	CcSEcCtD
Sirolimus—Dysuria—Doxorubicin—peripheral nervous system neoplasm	6.02e-05	0.000245	CcSEcCtD
Sirolimus—Neutropenia—Doxorubicin—peripheral nervous system neoplasm	6.02e-05	0.000245	CcSEcCtD
Sirolimus—Upper respiratory tract infection—Doxorubicin—peripheral nervous system neoplasm	5.98e-05	0.000243	CcSEcCtD
Sirolimus—Dizziness—Alitretinoin—peripheral nervous system neoplasm	5.98e-05	0.000243	CcSEcCtD
Sirolimus—Diarrhoea—Vincristine—peripheral nervous system neoplasm	5.96e-05	0.000242	CcSEcCtD
Sirolimus—Sweating—Epirubicin—peripheral nervous system neoplasm	5.94e-05	0.000242	CcSEcCtD
Sirolimus—Pollakiuria—Doxorubicin—peripheral nervous system neoplasm	5.94e-05	0.000242	CcSEcCtD
Sirolimus—Haematuria—Epirubicin—peripheral nervous system neoplasm	5.91e-05	0.00024	CcSEcCtD
Sirolimus—Hepatobiliary disease—Epirubicin—peripheral nervous system neoplasm	5.86e-05	0.000238	CcSEcCtD
Sirolimus—Weight increased—Doxorubicin—peripheral nervous system neoplasm	5.86e-05	0.000238	CcSEcCtD
Sirolimus—Epistaxis—Epirubicin—peripheral nervous system neoplasm	5.85e-05	0.000238	CcSEcCtD
Sirolimus—Weight decreased—Doxorubicin—peripheral nervous system neoplasm	5.82e-05	0.000237	CcSEcCtD
Sirolimus—Sinusitis—Epirubicin—peripheral nervous system neoplasm	5.82e-05	0.000236	CcSEcCtD
Sirolimus—Feeling abnormal—Etoposide—peripheral nervous system neoplasm	5.81e-05	0.000236	CcSEcCtD
Sirolimus—Hyperglycaemia—Doxorubicin—peripheral nervous system neoplasm	5.8e-05	0.000236	CcSEcCtD
Sirolimus—Nausea—Dactinomycin—peripheral nervous system neoplasm	5.79e-05	0.000235	CcSEcCtD
Sirolimus—Pneumonia—Doxorubicin—peripheral nervous system neoplasm	5.77e-05	0.000235	CcSEcCtD
Sirolimus—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	5.77e-05	0.000235	CcSEcCtD
Sirolimus—Dizziness—Vincristine—peripheral nervous system neoplasm	5.76e-05	0.000234	CcSEcCtD
Sirolimus—Vomiting—Alitretinoin—peripheral nervous system neoplasm	5.75e-05	0.000234	CcSEcCtD
Sirolimus—Infestation—Doxorubicin—peripheral nervous system neoplasm	5.74e-05	0.000233	CcSEcCtD
Sirolimus—Infestation NOS—Doxorubicin—peripheral nervous system neoplasm	5.74e-05	0.000233	CcSEcCtD
Sirolimus—Rash—Alitretinoin—peripheral nervous system neoplasm	5.7e-05	0.000232	CcSEcCtD
Sirolimus—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	5.69e-05	0.000231	CcSEcCtD
Sirolimus—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	5.67e-05	0.000231	CcSEcCtD
Sirolimus—Headache—Alitretinoin—peripheral nervous system neoplasm	5.66e-05	0.00023	CcSEcCtD
Sirolimus—Neuropathy peripheral—Doxorubicin—peripheral nervous system neoplasm	5.62e-05	0.000229	CcSEcCtD
Sirolimus—Haemoglobin—Epirubicin—peripheral nervous system neoplasm	5.59e-05	0.000227	CcSEcCtD
Sirolimus—Stomatitis—Doxorubicin—peripheral nervous system neoplasm	5.59e-05	0.000227	CcSEcCtD
Sirolimus—Rhinitis—Epirubicin—peripheral nervous system neoplasm	5.58e-05	0.000227	CcSEcCtD
Sirolimus—Body temperature increased—Etoposide—peripheral nervous system neoplasm	5.58e-05	0.000227	CcSEcCtD
Sirolimus—Abdominal pain—Etoposide—peripheral nervous system neoplasm	5.58e-05	0.000227	CcSEcCtD
Sirolimus—Conjunctivitis—Doxorubicin—peripheral nervous system neoplasm	5.58e-05	0.000227	CcSEcCtD
Sirolimus—Urinary tract infection—Doxorubicin—peripheral nervous system neoplasm	5.58e-05	0.000227	CcSEcCtD
Sirolimus—Haemorrhage—Epirubicin—peripheral nervous system neoplasm	5.57e-05	0.000226	CcSEcCtD
Sirolimus—Hypoaesthesia—Epirubicin—peripheral nervous system neoplasm	5.54e-05	0.000225	CcSEcCtD
Sirolimus—Vomiting—Vincristine—peripheral nervous system neoplasm	5.54e-05	0.000225	CcSEcCtD
Sirolimus—Asthenia—Cisplatin—peripheral nervous system neoplasm	5.53e-05	0.000225	CcSEcCtD
Sirolimus—Pharyngitis—Epirubicin—peripheral nervous system neoplasm	5.52e-05	0.000225	CcSEcCtD
Sirolimus—Sweating—Doxorubicin—peripheral nervous system neoplasm	5.5e-05	0.000224	CcSEcCtD
Sirolimus—Urinary tract disorder—Epirubicin—peripheral nervous system neoplasm	5.5e-05	0.000223	CcSEcCtD
Sirolimus—Rash—Vincristine—peripheral nervous system neoplasm	5.49e-05	0.000223	CcSEcCtD
Sirolimus—Dermatitis—Vincristine—peripheral nervous system neoplasm	5.49e-05	0.000223	CcSEcCtD
Sirolimus—Oedema peripheral—Epirubicin—peripheral nervous system neoplasm	5.48e-05	0.000223	CcSEcCtD
Sirolimus—Haematuria—Doxorubicin—peripheral nervous system neoplasm	5.47e-05	0.000222	CcSEcCtD
Sirolimus—Connective tissue disorder—Epirubicin—peripheral nervous system neoplasm	5.47e-05	0.000222	CcSEcCtD
Sirolimus—Urethral disorder—Epirubicin—peripheral nervous system neoplasm	5.46e-05	0.000222	CcSEcCtD
Sirolimus—Headache—Vincristine—peripheral nervous system neoplasm	5.46e-05	0.000222	CcSEcCtD
Sirolimus—Hepatobiliary disease—Doxorubicin—peripheral nervous system neoplasm	5.43e-05	0.000221	CcSEcCtD
Sirolimus—Epistaxis—Doxorubicin—peripheral nervous system neoplasm	5.41e-05	0.00022	CcSEcCtD
Sirolimus—Sinusitis—Doxorubicin—peripheral nervous system neoplasm	5.38e-05	0.000219	CcSEcCtD
Sirolimus—Nausea—Alitretinoin—peripheral nervous system neoplasm	5.37e-05	0.000218	CcSEcCtD
Sirolimus—Visual impairment—Epirubicin—peripheral nervous system neoplasm	5.36e-05	0.000218	CcSEcCtD
Sirolimus—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	5.27e-05	0.000214	CcSEcCtD
Sirolimus—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	5.2e-05	0.000211	CcSEcCtD
Sirolimus—Tinnitus—Epirubicin—peripheral nervous system neoplasm	5.19e-05	0.000211	CcSEcCtD
Sirolimus—Haemoglobin—Doxorubicin—peripheral nervous system neoplasm	5.18e-05	0.00021	CcSEcCtD
Sirolimus—Nausea—Vincristine—peripheral nervous system neoplasm	5.17e-05	0.00021	CcSEcCtD
Sirolimus—Cardiac disorder—Epirubicin—peripheral nervous system neoplasm	5.17e-05	0.00021	CcSEcCtD
Sirolimus—Rhinitis—Doxorubicin—peripheral nervous system neoplasm	5.16e-05	0.00021	CcSEcCtD
Sirolimus—Haemorrhage—Doxorubicin—peripheral nervous system neoplasm	5.15e-05	0.000209	CcSEcCtD
Sirolimus—Hypoaesthesia—Doxorubicin—peripheral nervous system neoplasm	5.12e-05	0.000208	CcSEcCtD
Sirolimus—Pharyngitis—Doxorubicin—peripheral nervous system neoplasm	5.11e-05	0.000208	CcSEcCtD
Sirolimus—Urinary tract disorder—Doxorubicin—peripheral nervous system neoplasm	5.09e-05	0.000207	CcSEcCtD
Sirolimus—Oedema peripheral—Doxorubicin—peripheral nervous system neoplasm	5.07e-05	0.000206	CcSEcCtD
Sirolimus—Asthenia—Etoposide—peripheral nervous system neoplasm	5.06e-05	0.000206	CcSEcCtD
Sirolimus—Connective tissue disorder—Doxorubicin—peripheral nervous system neoplasm	5.06e-05	0.000206	CcSEcCtD
Sirolimus—Angiopathy—Epirubicin—peripheral nervous system neoplasm	5.05e-05	0.000205	CcSEcCtD
Sirolimus—Urethral disorder—Doxorubicin—peripheral nervous system neoplasm	5.05e-05	0.000205	CcSEcCtD
Sirolimus—Immune system disorder—Epirubicin—peripheral nervous system neoplasm	5.03e-05	0.000204	CcSEcCtD
Sirolimus—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	5.02e-05	0.000204	CcSEcCtD
Sirolimus—Chills—Epirubicin—peripheral nervous system neoplasm	4.99e-05	0.000203	CcSEcCtD
Sirolimus—Pruritus—Etoposide—peripheral nervous system neoplasm	4.99e-05	0.000203	CcSEcCtD
Sirolimus—Visual impairment—Doxorubicin—peripheral nervous system neoplasm	4.96e-05	0.000202	CcSEcCtD
Sirolimus—Vomiting—Cisplatin—peripheral nervous system neoplasm	4.9e-05	0.000199	CcSEcCtD
Sirolimus—Rash—Cisplatin—peripheral nervous system neoplasm	4.86e-05	0.000197	CcSEcCtD
Sirolimus—Dermatitis—Cisplatin—peripheral nervous system neoplasm	4.85e-05	0.000197	CcSEcCtD
Sirolimus—Malnutrition—Epirubicin—peripheral nervous system neoplasm	4.85e-05	0.000197	CcSEcCtD
Sirolimus—Diarrhoea—Etoposide—peripheral nervous system neoplasm	4.83e-05	0.000196	CcSEcCtD
Sirolimus—FGF2—Signaling by ERBB2—AKT1—peripheral nervous system neoplasm	4.81e-05	0.000507	CbGpPWpGaD
Sirolimus—Tinnitus—Doxorubicin—peripheral nervous system neoplasm	4.8e-05	0.000195	CcSEcCtD
Sirolimus—MTOR—B Cell Activation—NRAS—peripheral nervous system neoplasm	4.78e-05	0.000505	CbGpPWpGaD
Sirolimus—FGF2—DAP12 signaling—AKT1—peripheral nervous system neoplasm	4.78e-05	0.000505	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	4.78e-05	0.000505	CbGpPWpGaD
Sirolimus—Cardiac disorder—Doxorubicin—peripheral nervous system neoplasm	4.78e-05	0.000194	CcSEcCtD
Sirolimus—Flatulence—Epirubicin—peripheral nervous system neoplasm	4.78e-05	0.000194	CcSEcCtD
Sirolimus—Tension—Epirubicin—peripheral nervous system neoplasm	4.76e-05	0.000193	CcSEcCtD
Sirolimus—FGF2—Signaling by NGF—NRAS—peripheral nervous system neoplasm	4.75e-05	0.000501	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—GNS—peripheral nervous system neoplasm	4.74e-05	0.0005	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—PTPN11—peripheral nervous system neoplasm	4.72e-05	0.000498	CbGpPWpGaD
Sirolimus—FGF2—B Cell Activation—HRAS—peripheral nervous system neoplasm	4.72e-05	0.000498	CbGpPWpGaD
Sirolimus—MTOR—Signaling by VEGF—AKT1—peripheral nervous system neoplasm	4.72e-05	0.000498	CbGpPWpGaD
Sirolimus—FGF2—Downstream signaling events of B Cell Receptor (BCR)—AKT1—peripheral nervous system neoplasm	4.71e-05	0.000498	CbGpPWpGaD
Sirolimus—Nervousness—Epirubicin—peripheral nervous system neoplasm	4.71e-05	0.000191	CcSEcCtD
Sirolimus—FGF2—Signaling Pathways—VIP—peripheral nervous system neoplasm	4.7e-05	0.000497	CbGpPWpGaD
Sirolimus—Back pain—Epirubicin—peripheral nervous system neoplasm	4.69e-05	0.000191	CcSEcCtD
Sirolimus—ABCB1—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	4.67e-05	0.000493	CbGpPWpGaD
Sirolimus—Angiopathy—Doxorubicin—peripheral nervous system neoplasm	4.67e-05	0.00019	CcSEcCtD
Sirolimus—Dizziness—Etoposide—peripheral nervous system neoplasm	4.67e-05	0.00019	CcSEcCtD
Sirolimus—Muscle spasms—Epirubicin—peripheral nervous system neoplasm	4.66e-05	0.000189	CcSEcCtD
Sirolimus—FGF2—Immune System—IFNB1—peripheral nervous system neoplasm	4.65e-05	0.000491	CbGpPWpGaD
Sirolimus—Immune system disorder—Doxorubicin—peripheral nervous system neoplasm	4.65e-05	0.000189	CcSEcCtD
Sirolimus—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	4.64e-05	0.000189	CcSEcCtD
Sirolimus—MTOR—Signaling by NGF—ERBB2—peripheral nervous system neoplasm	4.63e-05	0.000489	CbGpPWpGaD
Sirolimus—Chills—Doxorubicin—peripheral nervous system neoplasm	4.62e-05	0.000188	CcSEcCtD
Sirolimus—MTOR—Signaling Pathways—NTS—peripheral nervous system neoplasm	4.61e-05	0.000486	CbGpPWpGaD
Sirolimus—MTOR—Disease—PPP3R1—peripheral nervous system neoplasm	4.6e-05	0.000486	CbGpPWpGaD
Sirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—NRAS—peripheral nervous system neoplasm	4.58e-05	0.000483	CbGpPWpGaD
Sirolimus—Nausea—Cisplatin—peripheral nervous system neoplasm	4.57e-05	0.000186	CcSEcCtD
Sirolimus—SLCO1B1—Metabolism—NME1—peripheral nervous system neoplasm	4.54e-05	0.00048	CbGpPWpGaD
Sirolimus—MTOR—Signaling by SCF-KIT—HRAS—peripheral nervous system neoplasm	4.54e-05	0.000479	CbGpPWpGaD
Sirolimus—FGF2—NGF signalling via TRKA from the plasma membrane—HRAS—peripheral nervous system neoplasm	4.51e-05	0.000476	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—PTPN11—peripheral nervous system neoplasm	4.5e-05	0.000475	CbGpPWpGaD
Sirolimus—FGF2—DAP12 interactions—AKT1—peripheral nervous system neoplasm	4.5e-05	0.000475	CbGpPWpGaD
Sirolimus—FGF2—Fc epsilon receptor (FCERI) signaling—AKT1—peripheral nervous system neoplasm	4.5e-05	0.000475	CbGpPWpGaD
Sirolimus—FGF2—Signaling by FGFR in disease—AKT1—peripheral nervous system neoplasm	4.5e-05	0.000475	CbGpPWpGaD
Sirolimus—Ill-defined disorder—Epirubicin—peripheral nervous system neoplasm	4.5e-05	0.000183	CcSEcCtD
Sirolimus—MTOR—Integrated Breast Cancer Pathway—TP53—peripheral nervous system neoplasm	4.49e-05	0.000474	CbGpPWpGaD
Sirolimus—Vomiting—Etoposide—peripheral nervous system neoplasm	4.49e-05	0.000182	CcSEcCtD
Sirolimus—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	4.48e-05	0.000182	CcSEcCtD
Sirolimus—Anaemia—Epirubicin—peripheral nervous system neoplasm	4.48e-05	0.000182	CcSEcCtD
Sirolimus—MTOR—BDNF signaling pathway—HRAS—peripheral nervous system neoplasm	4.46e-05	0.000471	CbGpPWpGaD
Sirolimus—FGF2—Signaling by EGFR—AKT1—peripheral nervous system neoplasm	4.46e-05	0.000471	CbGpPWpGaD
Sirolimus—Agitation—Epirubicin—peripheral nervous system neoplasm	4.45e-05	0.000181	CcSEcCtD
Sirolimus—Rash—Etoposide—peripheral nervous system neoplasm	4.45e-05	0.000181	CcSEcCtD
Sirolimus—Dermatitis—Etoposide—peripheral nervous system neoplasm	4.44e-05	0.000181	CcSEcCtD
Sirolimus—FGF2—Signaling by EGFR in Cancer—AKT1—peripheral nervous system neoplasm	4.42e-05	0.000467	CbGpPWpGaD
Sirolimus—Headache—Etoposide—peripheral nervous system neoplasm	4.42e-05	0.00018	CcSEcCtD
Sirolimus—Flatulence—Doxorubicin—peripheral nervous system neoplasm	4.42e-05	0.00018	CcSEcCtD
Sirolimus—MTOR—Signaling Pathways—CD55—peripheral nervous system neoplasm	4.42e-05	0.000466	CbGpPWpGaD
Sirolimus—MTOR—Immune System—NCAM1—peripheral nervous system neoplasm	4.4e-05	0.000465	CbGpPWpGaD
Sirolimus—FGF2—Signaling by PDGF—AKT1—peripheral nervous system neoplasm	4.4e-05	0.000465	CbGpPWpGaD
Sirolimus—Tension—Doxorubicin—peripheral nervous system neoplasm	4.4e-05	0.000179	CcSEcCtD
Sirolimus—EIF4E—Signaling Pathways—GNAS—peripheral nervous system neoplasm	4.39e-05	0.000463	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—COX2—peripheral nervous system neoplasm	4.37e-05	0.000462	CbGpPWpGaD
Sirolimus—Malaise—Epirubicin—peripheral nervous system neoplasm	4.37e-05	0.000178	CcSEcCtD
Sirolimus—Nervousness—Doxorubicin—peripheral nervous system neoplasm	4.35e-05	0.000177	CcSEcCtD
Sirolimus—CYP3A7—Metabolism—GNS—peripheral nervous system neoplasm	4.35e-05	0.000459	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—HSD17B12—peripheral nervous system neoplasm	4.35e-05	0.000459	CbGpPWpGaD
Sirolimus—Syncope—Epirubicin—peripheral nervous system neoplasm	4.35e-05	0.000177	CcSEcCtD
Sirolimus—FGF2—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	4.34e-05	0.000458	CbGpPWpGaD
Sirolimus—MTOR—Downstream signaling of activated FGFR—HRAS—peripheral nervous system neoplasm	4.34e-05	0.000458	CbGpPWpGaD
Sirolimus—Leukopenia—Epirubicin—peripheral nervous system neoplasm	4.34e-05	0.000176	CcSEcCtD
Sirolimus—Back pain—Doxorubicin—peripheral nervous system neoplasm	4.34e-05	0.000176	CcSEcCtD
Sirolimus—FGF2—Disease—SLC2A1—peripheral nervous system neoplasm	4.33e-05	0.000457	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—PTPN11—peripheral nervous system neoplasm	4.32e-05	0.000456	CbGpPWpGaD
Sirolimus—Muscle spasms—Doxorubicin—peripheral nervous system neoplasm	4.31e-05	0.000175	CcSEcCtD
Sirolimus—FKBP1A—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	4.3e-05	0.000454	CbGpPWpGaD
Sirolimus—Palpitations—Epirubicin—peripheral nervous system neoplasm	4.28e-05	0.000174	CcSEcCtD
Sirolimus—MTOR—Signaling by ERBB4—HRAS—peripheral nervous system neoplasm	4.27e-05	0.000451	CbGpPWpGaD
Sirolimus—Loss of consciousness—Epirubicin—peripheral nervous system neoplasm	4.26e-05	0.000173	CcSEcCtD
Sirolimus—FGF2—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	4.23e-05	0.000447	CbGpPWpGaD
Sirolimus—Cough—Epirubicin—peripheral nervous system neoplasm	4.23e-05	0.000172	CcSEcCtD
Sirolimus—MTOR—Signaling by NGF—CASP3—peripheral nervous system neoplasm	4.2e-05	0.000444	CbGpPWpGaD
Sirolimus—Nausea—Etoposide—peripheral nervous system neoplasm	4.19e-05	0.00017	CcSEcCtD
Sirolimus—Hypertension—Epirubicin—peripheral nervous system neoplasm	4.18e-05	0.00017	CcSEcCtD
Sirolimus—CYP3A7—Metabolism—NME1—peripheral nervous system neoplasm	4.17e-05	0.00044	CbGpPWpGaD
Sirolimus—FGF2—B Cell Activation—AKT1—peripheral nervous system neoplasm	4.16e-05	0.00044	CbGpPWpGaD
Sirolimus—Ill-defined disorder—Doxorubicin—peripheral nervous system neoplasm	4.16e-05	0.000169	CcSEcCtD
Sirolimus—Anaemia—Doxorubicin—peripheral nervous system neoplasm	4.14e-05	0.000168	CcSEcCtD
Sirolimus—Myalgia—Epirubicin—peripheral nervous system neoplasm	4.13e-05	0.000168	CcSEcCtD
Sirolimus—Chest pain—Epirubicin—peripheral nervous system neoplasm	4.13e-05	0.000168	CcSEcCtD
Sirolimus—Arthralgia—Epirubicin—peripheral nervous system neoplasm	4.13e-05	0.000168	CcSEcCtD
Sirolimus—Agitation—Doxorubicin—peripheral nervous system neoplasm	4.12e-05	0.000167	CcSEcCtD
Sirolimus—Anxiety—Epirubicin—peripheral nervous system neoplasm	4.11e-05	0.000167	CcSEcCtD
Sirolimus—MTOR—Insulin Signaling—HRAS—peripheral nervous system neoplasm	4.1e-05	0.000433	CbGpPWpGaD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	4.1e-05	0.000167	CcSEcCtD
Sirolimus—MTOR—Downstream signal transduction—HRAS—peripheral nervous system neoplasm	4.08e-05	0.000431	CbGpPWpGaD
Sirolimus—Discomfort—Epirubicin—peripheral nervous system neoplasm	4.08e-05	0.000166	CcSEcCtD
Sirolimus—MTOR—EGF/EGFR Signaling Pathway—HRAS—peripheral nervous system neoplasm	4.06e-05	0.000429	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR—HRAS—peripheral nervous system neoplasm	4.06e-05	0.000429	CbGpPWpGaD
Sirolimus—Malaise—Doxorubicin—peripheral nervous system neoplasm	4.04e-05	0.000164	CcSEcCtD
Sirolimus—MTOR—Signaling by ERBB2—HRAS—peripheral nervous system neoplasm	4.04e-05	0.000426	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—ERBB2—peripheral nervous system neoplasm	4.03e-05	0.000425	CbGpPWpGaD
Sirolimus—Syncope—Doxorubicin—peripheral nervous system neoplasm	4.02e-05	0.000163	CcSEcCtD
Sirolimus—MTOR—DAP12 signaling—HRAS—peripheral nervous system neoplasm	4.02e-05	0.000424	CbGpPWpGaD
Sirolimus—Leukopenia—Doxorubicin—peripheral nervous system neoplasm	4.01e-05	0.000163	CcSEcCtD
Sirolimus—CYP3A7—Metabolism—COX2—peripheral nervous system neoplasm	4.01e-05	0.000424	CbGpPWpGaD
Sirolimus—MTOR—Signaling by SCF-KIT—AKT1—peripheral nervous system neoplasm	4.01e-05	0.000423	CbGpPWpGaD
Sirolimus—Confusional state—Epirubicin—peripheral nervous system neoplasm	3.99e-05	0.000162	CcSEcCtD
Sirolimus—MTOR—Disease—ENO2—peripheral nervous system neoplasm	3.99e-05	0.000421	CbGpPWpGaD
Sirolimus—FGF2—NGF signalling via TRKA from the plasma membrane—AKT1—peripheral nervous system neoplasm	3.99e-05	0.000421	CbGpPWpGaD
Sirolimus—SLCO1B1—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	3.97e-05	0.00042	CbGpPWpGaD
Sirolimus—Palpitations—Doxorubicin—peripheral nervous system neoplasm	3.96e-05	0.000161	CcSEcCtD
Sirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—HRAS—peripheral nervous system neoplasm	3.96e-05	0.000418	CbGpPWpGaD
Sirolimus—Oedema—Epirubicin—peripheral nervous system neoplasm	3.95e-05	0.000161	CcSEcCtD
Sirolimus—Anaphylactic shock—Epirubicin—peripheral nervous system neoplasm	3.95e-05	0.000161	CcSEcCtD
Sirolimus—Loss of consciousness—Doxorubicin—peripheral nervous system neoplasm	3.94e-05	0.00016	CcSEcCtD
Sirolimus—MTOR—BDNF signaling pathway—AKT1—peripheral nervous system neoplasm	3.94e-05	0.000416	CbGpPWpGaD
Sirolimus—Infection—Epirubicin—peripheral nervous system neoplasm	3.93e-05	0.00016	CcSEcCtD
Sirolimus—Cough—Doxorubicin—peripheral nervous system neoplasm	3.91e-05	0.000159	CcSEcCtD
Sirolimus—SLCO1B1—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	3.9e-05	0.000412	CbGpPWpGaD
Sirolimus—Shock—Epirubicin—peripheral nervous system neoplasm	3.89e-05	0.000158	CcSEcCtD
Sirolimus—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	3.88e-05	0.000158	CcSEcCtD
Sirolimus—Thrombocytopenia—Epirubicin—peripheral nervous system neoplasm	3.87e-05	0.000157	CcSEcCtD
Sirolimus—Hypertension—Doxorubicin—peripheral nervous system neoplasm	3.87e-05	0.000157	CcSEcCtD
Sirolimus—Tachycardia—Epirubicin—peripheral nervous system neoplasm	3.86e-05	0.000157	CcSEcCtD
Sirolimus—Skin disorder—Epirubicin—peripheral nervous system neoplasm	3.84e-05	0.000156	CcSEcCtD
Sirolimus—MTOR—Downstream signaling of activated FGFR—AKT1—peripheral nervous system neoplasm	3.83e-05	0.000405	CbGpPWpGaD
Sirolimus—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	3.82e-05	0.000155	CcSEcCtD
Sirolimus—Chest pain—Doxorubicin—peripheral nervous system neoplasm	3.82e-05	0.000155	CcSEcCtD
Sirolimus—Myalgia—Doxorubicin—peripheral nervous system neoplasm	3.82e-05	0.000155	CcSEcCtD
Sirolimus—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	3.82e-05	0.000155	CcSEcCtD
Sirolimus—Anxiety—Doxorubicin—peripheral nervous system neoplasm	3.8e-05	0.000155	CcSEcCtD
Sirolimus—MTOR—Integrated Breast Cancer Pathway—AKT1—peripheral nervous system neoplasm	3.79e-05	0.0004	CbGpPWpGaD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	3.79e-05	0.000154	CcSEcCtD
Sirolimus—MTOR—Signaling by FGFR in disease—HRAS—peripheral nervous system neoplasm	3.78e-05	0.000399	CbGpPWpGaD
Sirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—HRAS—peripheral nervous system neoplasm	3.78e-05	0.000399	CbGpPWpGaD
Sirolimus—MTOR—DAP12 interactions—HRAS—peripheral nervous system neoplasm	3.78e-05	0.000399	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB4—AKT1—peripheral nervous system neoplasm	3.77e-05	0.000398	CbGpPWpGaD
Sirolimus—Discomfort—Doxorubicin—peripheral nervous system neoplasm	3.77e-05	0.000153	CcSEcCtD
Sirolimus—Anorexia—Epirubicin—peripheral nervous system neoplasm	3.77e-05	0.000153	CcSEcCtD
Sirolimus—MTOR—Signaling by EGFR—HRAS—peripheral nervous system neoplasm	3.75e-05	0.000396	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—ERBB2—peripheral nervous system neoplasm	3.73e-05	0.000393	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR in Cancer—HRAS—peripheral nervous system neoplasm	3.72e-05	0.000392	CbGpPWpGaD
Sirolimus—MTOR—Signaling by PDGF—HRAS—peripheral nervous system neoplasm	3.7e-05	0.00039	CbGpPWpGaD
Sirolimus—Hypotension—Epirubicin—peripheral nervous system neoplasm	3.7e-05	0.00015	CcSEcCtD
Sirolimus—Confusional state—Doxorubicin—peripheral nervous system neoplasm	3.69e-05	0.00015	CcSEcCtD
Sirolimus—FKBP1A—Signaling Pathways—KNG1—peripheral nervous system neoplasm	3.68e-05	0.000389	CbGpPWpGaD
Sirolimus—Anaphylactic shock—Doxorubicin—peripheral nervous system neoplasm	3.66e-05	0.000149	CcSEcCtD
Sirolimus—Oedema—Doxorubicin—peripheral nervous system neoplasm	3.66e-05	0.000149	CcSEcCtD
Sirolimus—Infection—Doxorubicin—peripheral nervous system neoplasm	3.64e-05	0.000148	CcSEcCtD
Sirolimus—MTOR—Insulin Signaling—AKT1—peripheral nervous system neoplasm	3.62e-05	0.000382	CbGpPWpGaD
Sirolimus—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	3.6e-05	0.000146	CcSEcCtD
Sirolimus—MTOR—Downstream signal transduction—AKT1—peripheral nervous system neoplasm	3.6e-05	0.00038	CbGpPWpGaD
Sirolimus—Shock—Doxorubicin—peripheral nervous system neoplasm	3.6e-05	0.000146	CcSEcCtD
Sirolimus—FGF2—Immune System—HGF—peripheral nervous system neoplasm	3.59e-05	0.000379	CbGpPWpGaD
Sirolimus—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	3.59e-05	0.000146	CcSEcCtD
Sirolimus—MTOR—Signaling by FGFR—AKT1—peripheral nervous system neoplasm	3.58e-05	0.000378	CbGpPWpGaD
Sirolimus—MTOR—EGF/EGFR Signaling Pathway—AKT1—peripheral nervous system neoplasm	3.58e-05	0.000378	CbGpPWpGaD
Sirolimus—Thrombocytopenia—Doxorubicin—peripheral nervous system neoplasm	3.58e-05	0.000146	CcSEcCtD
Sirolimus—Insomnia—Epirubicin—peripheral nervous system neoplasm	3.58e-05	0.000145	CcSEcCtD
Sirolimus—Tachycardia—Doxorubicin—peripheral nervous system neoplasm	3.57e-05	0.000145	CcSEcCtD
Sirolimus—MTOR—Signaling by ERBB2—AKT1—peripheral nervous system neoplasm	3.57e-05	0.000377	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—ERBB2—peripheral nervous system neoplasm	3.56e-05	0.000376	CbGpPWpGaD
Sirolimus—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	3.55e-05	0.000144	CcSEcCtD
Sirolimus—Paraesthesia—Epirubicin—peripheral nervous system neoplasm	3.55e-05	0.000144	CcSEcCtD
Sirolimus—MTOR—DAP12 signaling—AKT1—peripheral nervous system neoplasm	3.55e-05	0.000375	CbGpPWpGaD
Sirolimus—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	3.54e-05	0.000144	CcSEcCtD
Sirolimus—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	3.53e-05	0.000143	CcSEcCtD
Sirolimus—MTOR—Signaling by NGF—NRAS—peripheral nervous system neoplasm	3.52e-05	0.000372	CbGpPWpGaD
Sirolimus—Somnolence—Epirubicin—peripheral nervous system neoplasm	3.52e-05	0.000143	CcSEcCtD
Sirolimus—FKBP1A—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	3.51e-05	0.00037	CbGpPWpGaD
Sirolimus—MTOR—B Cell Activation—HRAS—peripheral nervous system neoplasm	3.5e-05	0.000369	CbGpPWpGaD
Sirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—AKT1—peripheral nervous system neoplasm	3.5e-05	0.000369	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—VIP—peripheral nervous system neoplasm	3.49e-05	0.000369	CbGpPWpGaD
Sirolimus—Anorexia—Doxorubicin—peripheral nervous system neoplasm	3.49e-05	0.000142	CcSEcCtD
Sirolimus—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	3.48e-05	0.000142	CcSEcCtD
Sirolimus—FGF2—Signaling by NGF—HRAS—peripheral nervous system neoplasm	3.47e-05	0.000366	CbGpPWpGaD
Sirolimus—MTOR—Immune System—IFNB1—peripheral nervous system neoplasm	3.45e-05	0.000365	CbGpPWpGaD
Sirolimus—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	3.44e-05	0.00014	CcSEcCtD
Sirolimus—Hypotension—Doxorubicin—peripheral nervous system neoplasm	3.42e-05	0.000139	CcSEcCtD
Sirolimus—FGF2—Adaptive Immune System—ERBB2—peripheral nervous system neoplasm	3.42e-05	0.000361	CbGpPWpGaD
Sirolimus—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	3.41e-05	0.000139	CcSEcCtD
Sirolimus—Pain—Epirubicin—peripheral nervous system neoplasm	3.38e-05	0.000137	CcSEcCtD
Sirolimus—Constipation—Epirubicin—peripheral nervous system neoplasm	3.38e-05	0.000137	CcSEcCtD
Sirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—HRAS—peripheral nervous system neoplasm	3.35e-05	0.000354	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—PTPN11—peripheral nervous system neoplasm	3.34e-05	0.000353	CbGpPWpGaD
Sirolimus—MTOR—DAP12 interactions—AKT1—peripheral nervous system neoplasm	3.34e-05	0.000353	CbGpPWpGaD
Sirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—AKT1—peripheral nervous system neoplasm	3.34e-05	0.000353	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR in disease—AKT1—peripheral nervous system neoplasm	3.34e-05	0.000353	CbGpPWpGaD
Sirolimus—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	3.33e-05	0.000136	CcSEcCtD
Sirolimus—Insomnia—Doxorubicin—peripheral nervous system neoplasm	3.31e-05	0.000135	CcSEcCtD
Sirolimus—MTOR—Signaling by EGFR—AKT1—peripheral nervous system neoplasm	3.31e-05	0.000349	CbGpPWpGaD
Sirolimus—Paraesthesia—Doxorubicin—peripheral nervous system neoplasm	3.29e-05	0.000134	CcSEcCtD
Sirolimus—ABCB1—Metabolism—HSD17B12—peripheral nervous system neoplasm	3.28e-05	0.000346	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR in Cancer—AKT1—peripheral nervous system neoplasm	3.28e-05	0.000346	CbGpPWpGaD
Sirolimus—MTOR—Signaling by PDGF—AKT1—peripheral nervous system neoplasm	3.27e-05	0.000345	CbGpPWpGaD
Sirolimus—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	3.26e-05	0.000133	CcSEcCtD
Sirolimus—FGF2—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	3.26e-05	0.000344	CbGpPWpGaD
Sirolimus—Feeling abnormal—Epirubicin—peripheral nervous system neoplasm	3.26e-05	0.000132	CcSEcCtD
Sirolimus—Somnolence—Doxorubicin—peripheral nervous system neoplasm	3.25e-05	0.000132	CcSEcCtD
Sirolimus—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	3.23e-05	0.000131	CcSEcCtD
Sirolimus—MTOR—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	3.22e-05	0.00034	CbGpPWpGaD
Sirolimus—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	3.22e-05	0.000131	CcSEcCtD
Sirolimus—FKBP1A—Signaling Pathways—GNAS—peripheral nervous system neoplasm	3.22e-05	0.00034	CbGpPWpGaD
Sirolimus—MTOR—Disease—SLC2A1—peripheral nervous system neoplasm	3.21e-05	0.000339	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—PTPN11—peripheral nervous system neoplasm	3.21e-05	0.000339	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—PTPN11—peripheral nervous system neoplasm	3.19e-05	0.000337	CbGpPWpGaD
Sirolimus—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	3.18e-05	0.000129	CcSEcCtD
Sirolimus—ABCB1—HIF-1-alpha transcription factor network—AKT1—peripheral nervous system neoplasm	3.17e-05	0.000334	CbGpPWpGaD
Sirolimus—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	3.16e-05	0.000128	CcSEcCtD
Sirolimus—CYP3A5—Metabolism—GNS—peripheral nervous system neoplasm	3.14e-05	0.000332	CbGpPWpGaD
Sirolimus—Pain—Doxorubicin—peripheral nervous system neoplasm	3.13e-05	0.000127	CcSEcCtD
Sirolimus—Constipation—Doxorubicin—peripheral nervous system neoplasm	3.13e-05	0.000127	CcSEcCtD
Sirolimus—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	3.13e-05	0.000127	CcSEcCtD
Sirolimus—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	3.13e-05	0.000127	CcSEcCtD
Sirolimus—MTOR—B Cell Activation—AKT1—peripheral nervous system neoplasm	3.09e-05	0.000326	CbGpPWpGaD
Sirolimus—FGF2—Signaling by NGF—AKT1—peripheral nervous system neoplasm	3.07e-05	0.000324	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—NRAS—peripheral nervous system neoplasm	3.06e-05	0.000324	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	3.05e-05	0.000322	CbGpPWpGaD
Sirolimus—Feeling abnormal—Doxorubicin—peripheral nervous system neoplasm	3.02e-05	0.000123	CcSEcCtD
Sirolimus—CYP3A5—Metabolism—NME1—peripheral nervous system neoplasm	3.01e-05	0.000318	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PPIP5K2—peripheral nervous system neoplasm	2.99e-05	0.000316	CbGpPWpGaD
Sirolimus—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	2.99e-05	0.000122	CcSEcCtD
Sirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—AKT1—peripheral nervous system neoplasm	2.96e-05	0.000312	CbGpPWpGaD
Sirolimus—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	2.91e-05	0.000118	CcSEcCtD
Sirolimus—CYP3A5—Metabolism—COX2—peripheral nervous system neoplasm	2.9e-05	0.000306	CbGpPWpGaD
Sirolimus—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	2.89e-05	0.000118	CcSEcCtD
Sirolimus—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	2.89e-05	0.000118	CcSEcCtD
Sirolimus—MTOR—Cellular responses to stress—TP53—peripheral nervous system neoplasm	2.87e-05	0.000303	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—ENO2—peripheral nervous system neoplasm	2.87e-05	0.000303	CbGpPWpGaD
Sirolimus—Asthenia—Epirubicin—peripheral nervous system neoplasm	2.84e-05	0.000115	CcSEcCtD
Sirolimus—EIF4E—Immune System—NRAS—peripheral nervous system neoplasm	2.84e-05	0.000299	CbGpPWpGaD
Sirolimus—Pruritus—Epirubicin—peripheral nervous system neoplasm	2.8e-05	0.000114	CcSEcCtD
Sirolimus—FGF2—Signaling Pathways—KNG1—peripheral nervous system neoplasm	2.79e-05	0.000294	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—peripheral nervous system neoplasm	2.75e-05	0.000291	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—NRAS—peripheral nervous system neoplasm	2.71e-05	0.000286	CbGpPWpGaD
Sirolimus—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	2.71e-05	0.00011	CcSEcCtD
Sirolimus—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	2.7e-05	0.00011	CcSEcCtD
Sirolimus—MTOR—Immune System—HGF—peripheral nervous system neoplasm	2.67e-05	0.000282	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	2.66e-05	0.000281	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—ERBB2—peripheral nervous system neoplasm	2.64e-05	0.000279	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—ENO2—peripheral nervous system neoplasm	2.63e-05	0.000278	CbGpPWpGaD
Sirolimus—EIF4E—Gene Expression—MYC—peripheral nervous system neoplasm	2.63e-05	0.000277	CbGpPWpGaD
Sirolimus—Asthenia—Doxorubicin—peripheral nervous system neoplasm	2.63e-05	0.000107	CcSEcCtD
Sirolimus—FGF2—Immune System—PTPN11—peripheral nervous system neoplasm	2.62e-05	0.000277	CbGpPWpGaD
Sirolimus—Dizziness—Epirubicin—peripheral nervous system neoplasm	2.62e-05	0.000106	CcSEcCtD
Sirolimus—FGF2—Adaptive Immune System—NRAS—peripheral nervous system neoplasm	2.6e-05	0.000274	CbGpPWpGaD
Sirolimus—Pruritus—Doxorubicin—peripheral nervous system neoplasm	2.59e-05	0.000105	CcSEcCtD
Sirolimus—MTOR—Signaling by NGF—HRAS—peripheral nervous system neoplasm	2.58e-05	0.000272	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—ERBB2—peripheral nervous system neoplasm	2.54e-05	0.000268	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—ERBB2—peripheral nervous system neoplasm	2.52e-05	0.000266	CbGpPWpGaD
Sirolimus—Vomiting—Epirubicin—peripheral nervous system neoplasm	2.51e-05	0.000102	CcSEcCtD
Sirolimus—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	2.5e-05	0.000102	CcSEcCtD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—peripheral nervous system neoplasm	2.5e-05	0.000264	CbGpPWpGaD
Sirolimus—Rash—Epirubicin—peripheral nervous system neoplasm	2.49e-05	0.000101	CcSEcCtD
Sirolimus—Dermatitis—Epirubicin—peripheral nervous system neoplasm	2.49e-05	0.000101	CcSEcCtD
Sirolimus—Headache—Epirubicin—peripheral nervous system neoplasm	2.48e-05	0.000101	CcSEcCtD
Sirolimus—ABCB1—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	2.47e-05	0.000261	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—GNAS—peripheral nervous system neoplasm	2.44e-05	0.000257	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—BCHE—peripheral nervous system neoplasm	2.43e-05	0.000256	CbGpPWpGaD
Sirolimus—FGF2—Disease—PTPN11—peripheral nervous system neoplasm	2.42e-05	0.000256	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	2.42e-05	0.000255	CbGpPWpGaD
Sirolimus—Dizziness—Doxorubicin—peripheral nervous system neoplasm	2.42e-05	9.84e-05	CcSEcCtD
Sirolimus—EIF4E—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	2.41e-05	0.000254	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—GNS—peripheral nervous system neoplasm	2.37e-05	0.00025	CbGpPWpGaD
Sirolimus—Nausea—Epirubicin—peripheral nervous system neoplasm	2.35e-05	9.55e-05	CcSEcCtD
Sirolimus—Vomiting—Doxorubicin—peripheral nervous system neoplasm	2.33e-05	9.46e-05	CcSEcCtD
Sirolimus—SLCO1B1—Metabolism—SLC2A1—peripheral nervous system neoplasm	2.31e-05	0.000244	CbGpPWpGaD
Sirolimus—Rash—Doxorubicin—peripheral nervous system neoplasm	2.31e-05	9.38e-05	CcSEcCtD
Sirolimus—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	2.31e-05	9.37e-05	CcSEcCtD
Sirolimus—Headache—Doxorubicin—peripheral nervous system neoplasm	2.29e-05	9.32e-05	CcSEcCtD
Sirolimus—SLCO1B1—Metabolism—TH—peripheral nervous system neoplasm	2.28e-05	0.000241	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—AKT1—peripheral nervous system neoplasm	2.27e-05	0.00024	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—NME1—peripheral nervous system neoplasm	2.27e-05	0.00024	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—HRAS—peripheral nervous system neoplasm	2.24e-05	0.000237	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	2.24e-05	0.000236	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—BCHE—peripheral nervous system neoplasm	2.23e-05	0.000235	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—COX2—peripheral nervous system neoplasm	2.19e-05	0.000231	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—CASP3—peripheral nervous system neoplasm	2.19e-05	0.000231	CbGpPWpGaD
Sirolimus—Nausea—Doxorubicin—peripheral nervous system neoplasm	2.17e-05	8.84e-05	CcSEcCtD
Sirolimus—CYP3A7—Metabolism—SLC2A1—peripheral nervous system neoplasm	2.12e-05	0.000224	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—TH—peripheral nervous system neoplasm	2.09e-05	0.000221	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—HRAS—peripheral nervous system neoplasm	2.07e-05	0.000219	CbGpPWpGaD
Sirolimus—FGF2—Immune System—ERBB2—peripheral nervous system neoplasm	2.07e-05	0.000219	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—KNG1—peripheral nervous system neoplasm	2.07e-05	0.000219	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—HSD17B12—peripheral nervous system neoplasm	2.02e-05	0.000213	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—NRAS—peripheral nervous system neoplasm	2.01e-05	0.000212	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	1.99e-05	0.00021	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—HRAS—peripheral nervous system neoplasm	1.98e-05	0.000209	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—AKT1—peripheral nervous system neoplasm	1.98e-05	0.000209	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	1.97e-05	0.000208	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—peripheral nervous system neoplasm	1.95e-05	0.000206	CbGpPWpGaD
Sirolimus—MTOR—Immune System—PTPN11—peripheral nervous system neoplasm	1.95e-05	0.000205	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—NRAS—peripheral nervous system neoplasm	1.93e-05	0.000204	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—NRAS—peripheral nervous system neoplasm	1.92e-05	0.000203	CbGpPWpGaD
Sirolimus—FGF2—Disease—ERBB2—peripheral nervous system neoplasm	1.91e-05	0.000202	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—ENO2—peripheral nervous system neoplasm	1.9e-05	0.000201	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	1.9e-05	0.000201	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—GNAS—peripheral nervous system neoplasm	1.86e-05	0.000197	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.83e-05	0.000194	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—AKT1—peripheral nervous system neoplasm	1.83e-05	0.000193	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—ABCB1—peripheral nervous system neoplasm	1.83e-05	0.000193	CbGpPWpGaD
Sirolimus—EIF4E—Gene Expression—AKT1—peripheral nervous system neoplasm	1.82e-05	0.000192	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—GNAS—peripheral nervous system neoplasm	1.81e-05	0.000191	CbGpPWpGaD
Sirolimus—MTOR—Disease—PTPN11—peripheral nervous system neoplasm	1.8e-05	0.00019	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—MYC—peripheral nervous system neoplasm	1.79e-05	0.000189	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.77e-05	0.000187	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—AKT1—peripheral nervous system neoplasm	1.75e-05	0.000185	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—GNAS—peripheral nervous system neoplasm	1.71e-05	0.00018	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.71e-05	0.00018	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.7e-05	0.000179	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	1.68e-05	0.000177	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—ABCB1—peripheral nervous system neoplasm	1.68e-05	0.000177	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—BCHE—peripheral nervous system neoplasm	1.61e-05	0.00017	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.6e-05	0.000169	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	1.6e-05	0.000169	CbGpPWpGaD
Sirolimus—FGF2—Immune System—NRAS—peripheral nervous system neoplasm	1.58e-05	0.000166	CbGpPWpGaD
Sirolimus—MTOR—Immune System—ERBB2—peripheral nervous system neoplasm	1.54e-05	0.000162	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.54e-05	0.000162	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—TH—peripheral nervous system neoplasm	1.51e-05	0.00016	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—HRAS—peripheral nervous system neoplasm	1.47e-05	0.000155	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GNS—peripheral nervous system neoplasm	1.46e-05	0.000154	CbGpPWpGaD
Sirolimus—FGF2—Disease—NRAS—peripheral nervous system neoplasm	1.46e-05	0.000154	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—ENO2—peripheral nervous system neoplasm	1.44e-05	0.000152	CbGpPWpGaD
Sirolimus—MTOR—Disease—ERBB2—peripheral nervous system neoplasm	1.42e-05	0.00015	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	1.41e-05	0.000149	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—HRAS—peripheral nervous system neoplasm	1.41e-05	0.000148	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.4e-05	0.000148	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—NME1—peripheral nervous system neoplasm	1.4e-05	0.000148	CbGpPWpGaD
Sirolimus—FGF2—Disease—MYC—peripheral nervous system neoplasm	1.36e-05	0.000143	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	1.35e-05	0.000143	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—COX2—peripheral nervous system neoplasm	1.35e-05	0.000142	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.34e-05	0.000142	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.34e-05	0.000142	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.34e-05	0.000141	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—AKT1—peripheral nervous system neoplasm	1.3e-05	0.000137	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.26e-05	0.000133	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.25e-05	0.000132	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	1.25e-05	0.000132	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—AKT1—peripheral nervous system neoplasm	1.24e-05	0.000131	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—GNAS—peripheral nervous system neoplasm	1.24e-05	0.00013	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.22e-05	0.000128	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—BCHE—peripheral nervous system neoplasm	1.21e-05	0.000128	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—ABCB1—peripheral nervous system neoplasm	1.21e-05	0.000128	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.18e-05	0.000125	CbGpPWpGaD
Sirolimus—MTOR—Immune System—NRAS—peripheral nervous system neoplasm	1.17e-05	0.000123	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.16e-05	0.000122	CbGpPWpGaD
Sirolimus—FGF2—Immune System—HRAS—peripheral nervous system neoplasm	1.15e-05	0.000122	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—TH—peripheral nervous system neoplasm	1.14e-05	0.000121	CbGpPWpGaD
Sirolimus—MTOR—Disease—NRAS—peripheral nervous system neoplasm	1.08e-05	0.000114	CbGpPWpGaD
Sirolimus—FGF2—Disease—HRAS—peripheral nervous system neoplasm	1.06e-05	0.000112	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.03e-05	0.000109	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.02e-05	0.000108	CbGpPWpGaD
Sirolimus—FGF2—Immune System—AKT1—peripheral nervous system neoplasm	1.02e-05	0.000107	CbGpPWpGaD
Sirolimus—MTOR—Disease—MYC—peripheral nervous system neoplasm	1.01e-05	0.000106	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	9.94e-06	0.000105	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—HRAS—peripheral nervous system neoplasm	9.84e-06	0.000104	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MYC—peripheral nervous system neoplasm	9.49e-06	0.0001	CbGpPWpGaD
Sirolimus—FGF2—Disease—AKT1—peripheral nervous system neoplasm	9.4e-06	9.93e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—GNAS—peripheral nervous system neoplasm	9.32e-06	9.84e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CASP3—peripheral nervous system neoplasm	9.02e-06	9.53e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ENO2—peripheral nervous system neoplasm	8.85e-06	9.35e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—AKT1—peripheral nervous system neoplasm	8.69e-06	9.17e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—HRAS—peripheral nervous system neoplasm	8.56e-06	9.03e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—HRAS—peripheral nervous system neoplasm	7.9e-06	8.34e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—TP53—peripheral nervous system neoplasm	7.8e-06	8.23e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—NRAS—peripheral nervous system neoplasm	7.56e-06	7.98e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—AKT1—peripheral nervous system neoplasm	7.56e-06	7.98e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—BCHE—peripheral nervous system neoplasm	7.48e-06	7.9e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—HRAS—peripheral nervous system neoplasm	7.46e-06	7.87e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—SLC2A1—peripheral nervous system neoplasm	7.14e-06	7.53e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—MYC—peripheral nervous system neoplasm	7.05e-06	7.44e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—TH—peripheral nervous system neoplasm	7.03e-06	7.42e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—AKT1—peripheral nervous system neoplasm	6.98e-06	7.37e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—AKT1—peripheral nervous system neoplasm	6.58e-06	6.95e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TP53—peripheral nervous system neoplasm	5.79e-06	6.11e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GNAS—peripheral nervous system neoplasm	5.74e-06	6.06e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ABCB1—peripheral nervous system neoplasm	5.63e-06	5.95e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—HRAS—peripheral nervous system neoplasm	5.53e-06	5.84e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—AKT1—peripheral nervous system neoplasm	5.03e-06	5.3e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—AKT1—peripheral nervous system neoplasm	4.89e-06	5.16e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—AKT1—peripheral nervous system neoplasm	4.61e-06	4.87e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—AKT1—peripheral nervous system neoplasm	3.33e-06	3.52e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—AKT1—peripheral nervous system neoplasm	2.52e-06	2.66e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—AKT1—peripheral nervous system neoplasm	1.55e-06	1.64e-05	CbGpPWpGaD
